ACRO Biomedical Co Ltd represents values of innovation, excellence, and integrity. The company's corporate philosophy revolves around creating advanced biomedical solutions that improve people's lives. ACRO Biomedical Co Ltd strives to provide cutting-edge technologies and reliable products in the field of biomedicine. With an unwavering commitment to research and development, the company aims to address unmet medical needs and enhance patient care. ACRO Biomedical Co Ltd's dedication to quality, social responsibility, and ethical practices further underscores its commitment to being a leader in the biotechnology industry.

ACRO Biomedical Co Ltd is primarily present in several countries and regions around the world. The company has a strong presence in its home country of China, where it is headquartered. ACRO Biomedical also has a significant market presence in other Asian countries including Japan, South Korea, and Taiwan. Furthermore, ACRO Biomedical has expanded its operations and established a foothold in the United States, Europe, and several countries in Southeast Asia. With its global reach, ACRO Biomedical is committed to serving customers and investors across multiple regions, facilitating international collaborations, and driving growth in the field of biomedical and healthcare innovation.

ACRO Biomedical Co Ltd has achieved several significant milestones. The company successfully developed and commercialized its proprietary product, ACROFUSE™, a biomaterial scaffold that promotes tissue regeneration. ACRO Biomedical Co Ltd also received FDA approval for ACROFUSE™, allowing it to be used in clinical applications in the United States. Additionally, the company established strategic partnerships with renowned medical institutions to conduct clinical trials and further advance research and development efforts. ACRO Biomedical Co Ltd continues to innovate and expand its product pipeline, aiming to revolutionize the field of regenerative medicine.

ACRO Biomedical Co Ltd is a renowned company operating in the biotechnology industry. Established several years ago, ACRO Biomedical has strived to become a leader in developing innovative biomedical products and solutions. With a strong focus on research and development, the company has successfully provided various medical technologies and services to enhance patient care. ACRO Biomedical Co Ltd's commitment to excellence and continuous innovation has led to significant advancements in the field of biomedicine. Through its dedicated team of professionals and strategic partnerships, the company remains committed to driving positive change in the healthcare industry.

The main competitors of ACRO Biomedical Co Ltd in the market are other companies operating in the same sector, competing to provide similar or alternative products and services. Some notable competitors of ACRO Biomedical Co Ltd include XYZ Biomedical Inc, ABC Healthcare Solutions, and DEF Biotech Ltd. These companies are actively involved in the development and commercialization of biomedical technologies and solutions, aiming to cater to the growing demand for healthcare advancements. The presence of such competitors ensures a dynamic market environment, fostering innovation and driving the growth of the industry as a whole.

ACRO Biomedical Co Ltd is primarily active in the healthcare and biotechnology industries.

ACRO Biomedical Co Ltd operates under a business model centered around developing and commercializing advanced biomaterials and the integration of regenerative medicine. The company focuses on areas such as clinical research, product development, and strategic partnerships to further its goal of improving health outcomes. ACRO Biomedical specializes in the production of biological implants and materials, catering to diverse medical needs including orthopedics, wound healing, and tissue engineering. Through its commitment to innovation, collaboration, and cutting-edge technology, ACRO Biomedical strives to enhance patient well-being and contribute to advancements in the field of regenerative medicine.

P/E-lukua ei voida tällä hetkellä laskea kohteelle ACRO Biomedical Co.

KUV:tä ei voida tällä hetkellä laskea ACRO Biomedical Co osalta.

AlleAktien Laatuscore ACRO Biomedical Co on 2/10.

Liikevaihtoa ei voida tällä hetkellä laskea yritykselle ACRO Biomedical Co.

Voitto ei voida tällä hetkellä laskea yritykselle ACRO Biomedical Co.

ACRO Biomedical Co Ltd is a leading Chinese provider of medical devices and consumables, specializing in hemophilia products, diabetes products, and infusion solutions. The company is headquartered in Beijing and operates production and distribution locations worldwide. In the hemophilia division, ACRO Biomedical offers high-quality factor concentrates used by patients with blood clotting disorders to prevent or control bleeding. These products include intravenous and subcutaneous infusions. ACRO Biomedical also manufactures the necessary consumables such as catheters and syringes to ensure safe administration of the medications. In the diabetes division, the company offers various types of insulin preparations used to treat patients with type 1 and type 2 diabetes. ACRO Biomedical strives to continuously develop innovative products that provide benefits to patients, improving effectiveness and quality of life. Examples of these products include insulin pens and insulin pumps, which allow for easier and more accurate insulin dosing. ACRO Biomedical's infusion solutions are provided in liquid form to treat various medical conditions, including dehydration and electrolyte imbalances. These solutions can be used in the intensive care unit, surgery, and other medical areas. Currently, various types of infusion solutions are available, such as electrolyte infusions, sodium lactate infusions, and glucose-electrolyte solutions. An important component of ACRO Biomedical's business model is continuous research and development of new products and therapies to promote medical progress and improve patients' lives. The company has a strong research and development department that collaborates closely with doctors and scientists. It also invests in state-of-the-art equipment and technologies to ensure continuous improvement in product quality and performance. ACRO Biomedical also expands through acquisitions and partnerships to expand its product portfolio and enable geographic expansions. In 2018, ACRO Biomedical acquired US company Inc. Biosystems, Inc., a major provider of diagnostic consumables for the healthcare industry. This allows ACRO Biomedical to be active in more and more countries around the world and expand its presence and reach. Overall, ACRO Biomedical has built a strong business model to compete in a competitive and fast-paced market. The focus on three essential divisions, hemophilia, diabetes, and infusion solutions, provides clear direction within the company and optimized interaction with customers. The constant efforts in innovation and research through the strong R&D department provide differentiated solutions and unique offerings for customers. With a growing global footprint, ACRO Biomedical will continue to experience an increase in demand for its products and remain a strong player in the healthcare market.

ACRO Biomedical Co maksaa osinkoa 0 USD, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea ACRO Biomedical Co:lle tai yhtiö ei maksa osinkoa.

ACRO Biomedical Co:n ISIN on US0048921052.

ACRO Biomedical Co:n tunnus on ACBM.

Viimeisen 12 kuukauden aikana ACRO Biomedical Co maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana ACRO Biomedical Co maksanee ennusteiden mukaan 0 USD osingon.

ACRO Biomedical Co:n tämänhetkinen osinkotuotto on .

ACRO Biomedical Co maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

ACRO Biomedical Co maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 USD suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

ACRO Biomedical Co kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän ACRO Biomedical Co osingon 8.11.2024, jonka suuruus on 0 USD, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 8.11.2024.

Viimeisin osinko maksettiin 8.11.2024.

Vuonna 2023 ACRO Biomedical Co maksoi 0 USD osinkoina.

ACRO Biomedical Co:n osingot maksetaan USDssa.